InfuSystem approves $20 million stock buyback program starting July 2026

InfuSystem Holdings Inc. (NYSE American: INFU) announced that its board of directors approved a $20 million stock repurchase program. The program will run from July 1, 2026, through June 30, 2028, replacing the current authorization that expires June 30, 2026.

Under the existing program, the company repurchased approximately 1.6 million shares for about $11.9 million through March 31, 2026. The new program allows repurchases through open market purchases, private transactions, or other methods compliant with federal securities laws, including Rule 10b-18 under the Securities Exchange Act of 1934.

Chief Executive Officer Carrie Lachance stated the authorization continues the company's established buyback policy used to enhance shareholder value. "I believe the stock repurchase program demonstrates our confidence in being able to continue to execute with discipline, deliver profitable growth and drive long term value for the rest of 2026 and beyond," Lachance said.

InfuSystem operates as a healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers. The Rochester Hills, Michigan-based company operates through two platforms: Patient Services, which includes oncology, pain management and wound therapy businesses, and Device Solutions, which encompasses direct payer rentals, pump and consumable sales, and biomedical services.

The company maintains centers of excellence in Michigan, Kansas, California, Massachusetts, Texas and Ontario, Canada. Information in this article is based on a company press release.

You May Also Be Interested In

• Havas repurchases 5,000 shares under €50 million buyback plan
• Rezolve Ai shareholders approve $300M share repurchase program
• Cronos Group replaces broker for Canadian share repurchase program